Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Science

• Publication date

  1986-03-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/SCIENCE.3006246PMID 3006246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Solid-phase peptide synthesis.

  1996cited by this paper
• Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

  1985cited by this paper
• Turns in peptides and proteins.

  1985cited by this paper
• Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients

  1985cited by this paper
• Complete nucleotide sequence of the AIDS virus, HTLV-III

  1985cited by this paper
• Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus

  1985cited by this paper
• Expression in Escherichia coli of open reading frame gene segments of HTLV-III.

  1985cited by this paper
• Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

  1985cited by this paper
• Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoprotein.

  1985cited by this paper
• Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

  1985cited by this paper
• Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

  1985cited by this paper
• Nucleotide sequence of the AIDS virus, LAV.

  1985cited by this paper
• HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex

  1985cited by this paper
• Antibodies of predetermined specificity in biology and medicine.

  1984cited by this paper
• Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

  1984cited by this paper
• Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression.

  1984cited by this paper
• Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

  1984cited by this paper
• The antigenic structure of proteins: a reappraisal.

  1984cited by this paper
• Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

  1984cited by this paper
• Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome.

  1984cited by this paper
• Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

  1984cited by this paper
• Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS.

  1984cited by this paper
• Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

  1983cited by this paper
• Immunogenic structure of the influenza virus hemagglutinin.

  1982cited by this paper
• Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.

  1981cited by this paper
• Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

  1981cited by this paper
• Prediction of protein antigenic determinants from amino acid sequences.

  1981cited by this paper
• An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.

  1981cited by this paper
• New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates.

  1979cited by this paper
• Natural immunity in mice to the envelope glycoprotein of endogenous ecotropic type C viruses: neutralization of virus infectivity

  1977cited by this paper
• An improved polystyrene support for solid phase peptide synthesis.

  1976cited by this paper
• Prediction of protein conformation.

  1974cited by this paper
• Structural Proteins of Mammalian Oncogenic RNA Viruses: Murine Leukemia Virus Neutralization by Antisera Prepared Against Purified Envelope Glycoprotein

  1974cited by this paper

• Comprehensive Insights into the Molecular Basis of HIV Glycoproteins

  2024cites this paper
• C-terminal Motifs of HIV-1 gp41 as Possible Determinants of Viral Pathogenesis

  2022cites this paper
• Viral and Host Factors Regulating HIV-1 Envelope Protein Trafficking and Particle Incorporation

  2022cites this paper
• Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell–cell viral transmission and cell–cell fusion

  2018cites this paper
• Solution Structure and Membrane Interaction of the Cytoplasmic Tail of HIV-1 gp41 Protein.

  2017cites this paper
• Differentiating founder and chronic HIV envelope sequences

  2017cites this paper
• Correlation of Antibody Responses to a Peptide Antigen gp120-C5501–512/gp41732–744 with HIV Disease Progression

  2017cites this paper
• Mapping out the intricate relationship of the HIV envelope protein and the membrane environment.

  2017cites this paper
• Identifying possible sites for antibody neutralization escape: Implications for unique functional properties of the C-terminal tail of Human Immunodeficiency Virus Type 1 gp41.

  2016cites this paper
• Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion

  2015cites this paper
• Simian Immunodeficiency Virus Infection Evades Vaccine-Elicited Antibody Responses to V2 Region

  2015cites this paper
• The cytoplasmic tail of retroviral envelope glycoproteins.

  2015cites this paper
• Understanding the interplay between HIV-1 diversity, humoral immune responses and viral fitness

  2014cites this paper
• C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic

  2013influential citation
• The frantic play of the concealed HIV envelope cytoplasmic tail

  2013cites this paper
• Detailed Topology Mapping Reveals Substantial Exposure of the “Cytoplasmic” C-Terminal Tail (CTT) Sequences in HIV-1 Env Proteins at the Cell Surface

  2013cites this paper
• An Integrated Peptide-Antigen Microarray on Plasmonic Gold Films for Sensitive Human Antibody Profiling

  2013cites this paper
• Study of the HIV-2 Env Cytoplasmic Tail Variability and Its Impact on Tat, Rev and Nef

  2013cites this paper
• Développement d'anticorps monoclonaux humains de type IgA dirigés contre la partie C-terminale de la protéine d'enveloppe gp41 du VIH-1

  2013cites this paper
• Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell-cell fusion assay.

  2012cites this paper
• Experimental Determination of the Topology of the HIV-1 gp41 C-Terminal Tail

  2012influential citation
• The Tale of the Long Tail: the Cytoplasmic Domain of HIV-1 gp41

  2012cites this paper
• Evidence against Extracellular Exposure of a Highly Immunogenic Region in the C-Terminal Domain of the Simian Immunodeficiency Virus gp41 Transmembrane Protein

  2011cites this paper
• HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

  2011cites this paper
• HIV-1 Glycoprotein Immunogenicity

  2011cites this paper
• The Role of Dynamin in HIV Type 1 Env-Mediated Cell–Cell Fusion

  2011cites this paper
• Novel Immunogens based on the gp41 protein of Human Immunodeficiency Virus type 1 and Display Systems for their Affinity Maturation

  2011cites this paper
• Highly Conserved Structural Properties of the C-terminal Tail of HIV-1 gp41 Protein Despite Substantial Sequence Variation among Diverse Clades

  2011cites this paper
• Membrane topology analysis of HIV-1 envelope glycoprotein gp41

  2010cites this paper
• Development of Broadly Reactive HIV-1/AIDS Virus-like Particle Vaccines

  2010cites this paper
• Topology of the C-Terminal Tail of HIV-1 gp41: Differential Exposure of the Kennedy Epitope on Cell and Viral Membranes

  2010cites this paper
• P12-04. Topology of the C-terminal tail of HIV-1 gp41: Differential exposure of the Kennedy epitope on cell and viral membranes

  2009cites this paper
• Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain during the Membrane Fusion Process

  2008cites this paper
• Opposite Immune Reactivity of Serum IgG and Secretory IgA to Conformational Recombinant Proteins Mimicking V1/V2 Domains of Three Different HIV Type 1 Subtypes Depending on Glycosylation

  2008cites this paper
• Peptide P5 (residues 628–683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection

  2008cites this paper
• Effects of arginine‐glycine‐aspartic acid (RGD) containing snake venom peptides on parthenogenetic development and in vitro fertilization of bovine oocytes

  2007cites this paper
• Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.

  2007cites this paper
• Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

  2007cites this paper
• The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function

  2005influential citation
• An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.

  2005cites this paper
• The complex antigenicity of a small external region of the C‐terminal tail of the HIV‐1 gp41 envelope protein: a lesson in epitope analysis

  2005cites this paper
• Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion.

  2005influential citation
• Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in infected individuals grouped according to CD4+ cell levels

  2004cites this paper
• Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine Regimen

  2003cites this paper
• A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion.

  2003influential citation
• Evidence for Mixed Membrane Topology of the Newcastle Disease Virus Fusion Protein

  2003cites this paper
• Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients

  2003cites this paper
• Use of Plant Virus-Based Expression Systems for the Production of HIV Vaccines

  2002cites this paper
• Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain.

  2002cites this paper
• HIV‐1 gp120 Proteins and gp160 Peptides Are Toxic to Brain Endothelial Cells and Neurons: Possible Pathway for HIV Entry into the Brain and HIV‐Associated Dementia

  2002influential citation
• Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus.

  2002cites this paper
• Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tail of a neutralizing antibody escape mutant of human immunodeficiency virus type 1

  2001cites this paper
• Cowpea mosaic virus as a vaccine carrier of heterologous antigens

  2001cites this paper
• New insights into protective humoral responses and HIV vaccines.

  2001cites this paper
• Engineering Regulable Escherichia coliβ-Galactosidases as Biosensors for Anti-HIV Antibody Detection in Human Sera*

  2001cites this paper
• Ability of Integrins to Mediate Fertilization, Intracellular Calcium Release, and Parthenogenetic Development in Bovine Oocytes1

  2000cites this paper
• Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.

  2000cites this paper
• Removal of catalytic activity by EDTA from antibody light chain

  2000cites this paper
• How and why 41S-2 antibody subunits acquire the ability to catalyze decomposition of the conserved sequence of gp41 of HIV-1

  2000cites this paper
• Catalytic activity of antibody light chain to gp41: a consideration of refolding in relation to activation mechanism.

  2000cites this paper
• Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1.

  2000influential citation
• Super catalytic antibody [I]: decomposition of targeted protein by its antibody light chain.

  1999cites this paper
• Chapter 2 - Peptide-carrier conjugation

  1999cites this paper
• Cowpea mosaic virus-based vaccines.

  1999cites this paper
• The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope.

  1998influential citation
• Scope for using plant viruses to present epitopes from animal pathogens

  1998cites this paper
• Genetic variation of HIV type 1: relevance of interclade variation to vaccine development.

  1998cites this paper
• “Virosomes”, a new liposome-like vaccine delivery system

  1998cites this paper
• Presentation of heterologous peptides on plant viruses: genetics, structure, and function.

  1997cites this paper
• Structure of the Fab fragment from a neutralizing monoclonal antibody directed against an epitope of gp41 from HIV-1.

  1997cites this paper
• Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

  1997cites this paper
• A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE

  1997cites this paper
• HIV/SIV glycoproteins: structure-function relationships.

  1997cites this paper
• Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.

  1996cites this paper
• env gene sequences of primary HIV type 1 isolates of subtypes B, C, D, E, and F obtained from the World Health Organization Network for HIV Isolation and Characterization.

  1996cites this paper
• B-Cell Sites in the HIV Glycoproteins

  1996cites this paper
• Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein.

  1996cites this paper
• The development of cowpea mosaic virus as a potential source of novel vaccines.

  1996cites this paper
• An efficient method for the rescue and analysis of functional HIV‐1 env genes: evidence for recombination in the vicinity of the tat/rev splice site

  1996cites this paper
• Short Communication: env Gene Sequences of Primary HIV Type 1 Isolates of Subtypes B, C, D, E, and F Obtained from the World Health Organization Network for HIV Isolation and Characterization

  1996cites this paper
• Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine.

  1995cites this paper
• Characterization of immune suppression by a synthetic HIV gp41 peptide.

  1995cites this paper
• Anti-human immunodeficiency virus immunoconjugates.

  1995cites this paper
• Human Immunodeficiency Virus Type 1-Neutralizing Antibodies Raised to a Glycoprotein 41 Peptide Expressed on the Surface of a Plant Virus

  1995cites this paper
• Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype.

  1995cites this paper
• An approach for an immunoaffinity AIDS sensor using the conservative region of the HIV envelope protein (gp41) and its monoclonal antibody.

  1995cites this paper
• The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine.

  1995cites this paper
• Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

  1994cites this paper
• Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.

  1994cites this paper
• Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.

  1994cites this paper
• Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.

  1994cites this paper
• Immune responses to epitopes inserted in Salmonella flagellin.

  1994cites this paper
• Variability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben

  1994cites this paper
• NADPH-cytochrome c reductase from human neutrophil membranes: purification, characterization and localization.

  1994cites this paper
• Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

  1993cites this paper
• Synthetic peptides as diagnostic tools in virology.

  1993cites this paper
• Identification of four antibody‐binding sites in the envelope proteins of simian immunodeficiency virus, SIVsm

  1993cites this paper
• Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.

  1993cites this paper
• Bifunctional cross-linking reagents and methods to obtain the peptide-carrier conjugates

  1993cites this paper
• Three‐dimensional structure and antigenicity of transmembrane‐protein peptides of the human immunodeficiency virus type 1

  1993cites this paper